QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Trial details
- Registry ID
- NCT03853317
- Phase
- Phase 2
The FDA approved Avelumab ((BAVENCIO® injection, for intravenous [IV] use)) on 23 Mar 2017.
Drug identity checked against registry records
Also recorded as (BAVENCIO® injection, for intravenous [IV] use)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyNCT03853317 | IBRX | Phase 2 | Terminated | 2021-09-29Actual |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyNCT04215146 | Oncolytics Biotech | Phase 2 | Active not recruiting | 2022-08-01Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2017-03-23Day | Avelumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761049", "applicant_as_listed_by_fda": "EMD SERONO INC", "brand_names": ["BAVENCIO"], "active_ingredients": ["AVELUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20170323", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |